Shots:
- Radiopharm Theranostics has reported that the final patient has been dosed in its US P-IIb imaging trial of RAD 101, evaluating recurrent brain metastases in patients with solid tumors. 1EP readout is expected in Jun’26, with plans to advance RAD 101 into a US P-III pivotal trial
- The P-IIb trial is assessing 18F-RAD101 in 30 pts with recurrent brain metastases, focusing on concordance with MRI imaging. Interim data showed 90% concordance with MRI, meeting the 1EP
- RAD 101 is a small-molecule imaging agent targeting FASN, an enzyme protein overexpressed in many solid tumors, including brain metastases. The agent has received FDA FTD to help differentiate true recurrence from treatment effects, including leptomeningeal disease
Ref: Radiopharm | Image: Radiopharm | Press Release
Related News: SynOx Therapeutics Reports Topline P-III (TANGENT) Trial Results on Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
